Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF

Autor:	W. Herbert Haught, James E. Udelson, Russell Fileccia, Howard J. Eisen, Douglas Gregory, Richard D. Patten, Patricia Wedge, Divya Gupta, Jeremy M. Konstam, Marvin A. Konstam, Ravi Dhingra, Matthew Romeling, Michael S. Kiernan, Paul C. Gordon, Freny Vaghaiwalla Mody, Lynne Wagoner, Kenneth S. Korr, Arthur Chandler
Rok vydání:	2016
Předmět:	medicine.medical_specialty business.industry Tolvaptan Acute effect medicine.disease Heart failure Arginine vasopressin receptor 2 Internal medicine medicine Cardiology In patient Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of Cardiac Failure. 22:939
ISSN:	1071-9164
DOI:	10.1016/j.cardfail.2016.09.009
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7da75fa3b5ed9243ff7d290e4072e10a https://doi.org/10.1016/j.cardfail.2016.09.009 Zobrazit plný text záznamu Full Text from ScienceDirect